secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001213900-25-103661
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31
--------------------------------------------------------------------------------

- Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.
- Company has appealed to Nasdaq Listing and Hearing Review Council; also seeks OTC Markets trading.
- $4.75M Series E Preferred financing contingent on Nasdaq listing; funding now uncertain.
- Early clinical data for CER-1236 in three AML patients shows rapid cell expansion and no toxicity.
- Company reviewing cash resources and financing alternatives; no assurance of funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/0001213900-25-103661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/ea0263036-8k_cerothera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-103661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer